The Diversified Offerings of 9 Transgenic
Animal Strains Platforms supports Solid Growth in Drug
Discovery Services
VICTORIA, May 30, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF)
announces that its proprietary, high-throughput B-cell and phage
display platforms have garnered a lot of attention as of late, and
for a good reason. These species-independent platforms allow for
high-throughput and more efficient antibody discovery than
traditional hybridoma-based counterparts and are readily adapted
for use with fully-human transgenic animals, compounding the
benefits for the Company's clients.
In recent weeks and months, IPA has been engaged by several
large pharmaceutical companies to conduct work using transgenic
animals from Ligand Pharmaceutics (distributors of OmniRat™,
OmniMouse™, OmniFlic™, and OmniChicken™), Ablexis (distributors of
AlivaMab®), Harbour BioMed (distributors of Harbour Mice®, an
undisclosed transgenic knock-out animal, Alloy Therapeutics
(Distributors of Alloy Mice®) and Trianni (distributors of Trianni
Mice®).
IPA announced today that B-cell and phage display programs have
launched in seven of the above nine platforms, and three of these
programs are being trialed by a single client in two different
discovery platforms simultaneously.
"This unprecedented growth in the demand and use of alternative
transgenic species and strains is a client solicitation that IPA
has been anticipating, and is fully prepared to respond to," stated
Dr. Jennifer Bath, President and CEO
of IPA. "The requests have been well distributed across our
locations worldwide and continue to engage all three of our global,
antibody manufacturing sites." It is widely believed that fully
human antibodies manufactured through transgenic animal use will
witness a continually growing demand, and Dr. Bath confirms this,
furthering the belief that the Company's unique ability to handle
the variety of transgenic species, at a global, high-capacity,
uniquely positions the Company at the forefront of this industry
trend.
Extension of Warrant Expiry Dates
The Company also announces that it will apply to the TSX Venture
Exchange to extend the expiry date of 875,000 share purchase
warrants issued in a private placement financing on June 18, 2019 (see news release dated
June 19, 2018). The share
purchase warrants are exercisable at a price of $1.00 per share and the expiry date is being
extended from June 18, 2019 to
June 18, 2020. The extension of
the expiry date is subject to the acceptance of the TSX Venture
Exchange.
About ImmunoPrecise Antibodies Ltd.
IPA is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
IPA operates from state-of-the-art laboratory facilities located
at the Vancouver Island Technology Park in Victoria,
British Columbia, in collaboration
with its wholly-owned subsidiary operations at U-Protein Express
B.V., in the Life Science Incubator, Utrecht, and ModiQuest
Research, Oss, both in the Netherlands. The Company operates globally to
offer antibody services from target analysis to pre-clinical
studies.
The services offered to clients include antibody discovery
against a broad spectrum of antigens, including challenging
targets. Amongst these services, the Company offers hybridoma
production, B-cell services, and a variety of phage display
platforms. The Company also provides a broad range of supporting
services including immunologically-based assays, recombinant
protein manufacturing, humanization, optimization, stable cell line
development, and advanced solutions to challenges faced by clients
in antibody-related research and development. The antibodies
produced by IPA target a wide variety of therapeutic, diagnostic
and research applications.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by IPA in light of its experience and its perception
of historical trends, current conditions and expected future
developments. However, whether actual results and developments will
conform to IPA's expectations and predictions is subject to any
number of risks, assumptions and uncertainties. Many factors could
cause IPA's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in IPA's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
IPA undertakes no obligation to publicly update or revise such
information, whether as a result of new information, future events
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.